Nicole Ducharme, DO
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1346208394
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Amarin Pharma, Inc. accounts for 74.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $12,330 and has fallen 99.9% since, to $13 in 2024.
Across 63 payments — averaging $280.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$13K
- Corcept Therapeutics$4K
- AstraZeneca$398
- Dexcom, Inc.$127
- Medtronic$72
- Amgen$40
- plus $137 from 7 others
What the payments were for
- Consulting fees$2,25013%
- Speaking & faculty fees$10,18058%
- Travel & lodging$3,61520%
- Food & beverage$1,6379%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 28 | $13,236 |
| Corcept Therapeutics | 7 | $3,683 |
| AstraZeneca | 12 | $398 |
| Dexcom, Inc. | 4 | $127 |
| Medtronic(2 entities) | 2 | $72 |
| Amgen(2 entities) | 2 | $40 |
| Pfizer | 2 | $33 |
| Insulet Corporation | 1 | $28 |
| Boehringer Ingelheim | 1 | $19 |
| Radius Health, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$12,714
- Korlym$3,562
- FARXIGA$274
- DEXCOM G6 TRANSMITTER$116
How this compares
$17,694 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 558 | $740,199 |
| OzempicSemaglutide | 430 | $512,510 |
| FarxigaDapagliflozin Propanediol | 221 | $191,795 |
| JardianceEmpagliflozin | 168 | $146,351 |
| TrulicityDulaglutide | 93 | $123,297 |
| Xigduo XrDapaglifloz Propaned/Metformin | 125 | $112,544 |
| VascepaIcosapent Ethyl | 121 | $78,333 |
| Repatha SureclickEvolocumab | 100 | $72,630 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $63,711 |
| Humalog Kwikpen U-200Insulin Lispro | 48 | $59,462 |
| ForteoTeriparatide | 12 | $51,562 |
| Tresiba Flextouch U-100Insulin Degludec | 102 | $49,621 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $48,554 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $45,343 |
| Humalog Kwikpen U-100Insulin Lispro | 104 | $43,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $12 | $922,177678 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $19 | $201,171235 claims |
| AstraZenecaFarxiga | $398 | $191,795221 claims |
| AbbVieSynthroid | $15 | $13,564173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Janet McGillSaint Louis$212K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
- Julie SilversteinSaint Louis$49K
- Michael WhyteSaint Louis$40K
- Alexis McKeeSaint Louis$37K
- Sandeep DhindsaSaint Louis$36K
- Thomas NickolasSaint Louis$35K
- K ThampySaint Louis$35K
- Garry TobinSaint Louis$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.